Top

Published in:

18-04-2022 | Heart Transplantation

Donor substance abuse and heart transplantation outcomes

Authors: Mohammad Sabra, Onyedika Ilonze, Roopa A. Rao, Kashif Saleem, Maya E. Guglin

Published in: Heart Failure Reviews | Issue 1/2023

Abstract

Heart failure continues to account for millions of cases and deaths worldwide. Heart transplant is the gold standard for treatment of advanced heart failure. Unfortunately, the supply of donor hearts continues to be limited with the increase in demand for heart transplantation. In this review, we aim to explore the safety and efficacy of using hearts from donors with history of substance use. Despite the theoretical effect of cocaine and alcohol on the cardiovascular system, several studies demonstrate no difference in outcomes (overall survival, graft rejection, graft vasculopathy) when using hearts from patients with history of cocaine and alcohol use. The opioid epidemic has expanded the potential donor pool where the current studies have not shown any adverse outcomes when considering donors with history of opioid use. The currently available evidence would support the use of donor hearts from patients with history of alcohol, cocaine, opioids, and marijuana use. Further studies are needed to evaluate the safety of using donor hearts from patients with history of nicotine use.

Truby LK, Rogers JG (2020) Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC Heart failure 8:523–536CrossRef

Vaduganathan M, Machado SR, DeFilippis EM et al (2019) Organ Donation and Drug Intoxication-Related Deaths in the United States. N Engl J Med 380:597–599CrossRef

Mehra MR, Jarcho JA, Cherikh W et al (2018) The Drug-Intoxication Epidemic and Solid-Organ Transplantation. N Engl J Med 378:1943–1945CrossRef

Shea KJ, Sopko NA, Ludrosky K et al (2007) The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation. Euro J Cardio-Thoracic Surg : Official J Euro Assoc Cardio-thoracic Surg 31:452–6; discussion 456

Baran DA, Lansinger J, Long A et al (2021) Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety. Circ Heart Fail 14:e007433

Havakuk O, Rezkalla SH, Kloner RA (2017) The Cardiovascular Effects of Cocaine. J Am Coll Cardiol 70:101–113CrossRef

Houser SL, MacGillivray T, Aretz HT (2000) The impact of cocaine on the donor heart: a case report. J Heart Lung Transplant 19:609–611CrossRef

Costanzo MR, Dipchand A, Starling R et al (2010) The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29:914–956CrossRef

Jayarajan S, Taghavi S, Komaroff E et al (2015) Long-term outcomes in heart transplantation using donors with a history of past and present cocaine use. Eur J Cardiothorac Surg 47:e146–e150CrossRef

10.

Freimark D, Czer LS, Admon D et al (1994) Donors with a history of cocaine use: effect on survival and rejection frequency after heart transplantation. J Heart Lung Transplant 13:1138–1144

11.

Sorabella RA, Guglielmetti L, Kantor A et al (2015) Cardiac Donor Risk Factors Predictive of Short-Term Heart Transplant Recipient Mortality: An Analysis of the United Network for Organ Sharing Database. Transpl Proc 47:2944–2951CrossRef

12.

Brieke A, Krishnamani R, Rocha MJ et al (2008) Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant 27:1350–1352CrossRef

13.

Vieira JL, Cherikh WS, Lindblad K, Stehlik J, Mehra MR (2020) Cocaine use in organ donors and long-term outcome after heart transplantation: An International Society for Heart and Lung Transplantation registry analysis. J Heart Lung Transplant 39:1341–1350CrossRef

14.

Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA (2013) Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail 6:300–309CrossRef

15.

Okoh AK, Chan O, Schultheis M et al (2020) Association between increased-risk donor social behaviors and recipient outcomes after heart transplantation. Clin Transplant 34:e13787

16.

Laonigro I, Correale M, Di Biase M, Altomare E (2009) Alcohol abuse and heart failure. Eur J Heart Fail 11:453–462CrossRef

17.

Takkenberg JJ, Wang HM, Trento A et al (1997) The effect of chronic alcohol use on the heart before and after transplantation in an experimental model in the rat. J Heart Lung Transplant 16:939–945

18.

Newman J, Liebo M, Lowes BD et al (2019) The effect of donor alcohol abuse on outcomes following heart transplantation. Clini Transplant 33:e13461

19.

Freimark D, Aleksic I, Trento A et al (1996) Hearts from donors with chronic alcohol use: a possible risk factor for death after heart transplantation. J Heart Lung Transplant 15:150–159

20.

Houyel L, Petit J, Nottin R, Duffet JP, Macé L, Neveux JY (1992) Adult heart transplantation: adverse role of chronic alcoholism in donors on early graft function. J Heart Lung Transplant 11:1184–1187

21.

De La Zerda DJ, Cohen O, Beygui RE, Kobashigawa J, Hekmat D, Laks H (2007) Alcohol use in donors is a protective factor on recipients’ outcome after heart transplantation. Transplantation 83:1214–1218CrossRef

22.

Jacob KA, de Heer LM, de Heer F, Kluin J (2015) Chronic alcoholic donors in heart transplantation: A mortality meta-analysis. Int J Cardiol 191:7–10CrossRef

23.

Taghavi S, Jayarajan SN, Komaroff E et al (2015) Use of Heavy Drinking Donors in Heart Transplantation is Not Associated With Worse Mortality. Transplantation 99:1226–1230CrossRef

24.

Tsao CI, Chen RJ, Chou NK et al (2008) The influence of donor characteristics on survival after heart transplantation. Transpl Proc 40:2636–2637CrossRef

25.

Burke GM, Genuardi M, Shappell H, D’Agostino RB Sr, Magnani JW (2017) Temporal Associations Between Smoking and Cardiovascular Disease, 1971 to 2006 (from the Framingham Heart Study). Am J Cardiol 120:1787–1791CrossRef

26.

Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA (1962) Cigarette smoking and coronary heart disease. Combined experience of the Albany and Framingham studies. The New England J Med 266:796–801

27.

Freund KM, Belanger AJ, D'Agostino RB, Kannel WB (1993) The health risks of smoking. The Framingham Study: 34 years of follow-up. Annal Epidemiol 3:417–24

28.

Khanna AK, Xu J, Uber PA, Burke AP, Baquet C, Mehra MR (2009) Tobacco smoke exposure in either the donor or recipient before transplantation accelerates cardiac allograft rejection, vascular inflammation, and graft loss. Circulation 120:1814–1821CrossRef

29.

Rickenbacher PR, Pinto FJ, Lewis NP et al (1995) Correlation of donor characteristics with transplant coronary artery disease as assessed by intracoronary ultrasound and coronary angiography. Am J Cardiol 76:340–345CrossRef

30.

Hussain Z, Yu M, Wozniak A et al (2021) Impact of donor smoking history on post heart transplant outcomes: A propensity-matched analysis of ISHLT registry. Clin Transplant 35:e14127

31.

Finger MA, Cipullo R, Rossi Neto JM et al (2019) Donor hypernatremia and smoking addiction contribute to primary graft failure in heart transplantation. Clin Transplant 33:e13693

32.

Phillips KG, Ranganath NK, Malas J et al (2019) Impact of the Opioid Epidemic on Heart Transplantation: Donor Characteristics and Organ Discard. Ann Thorac Surg 108:1133–1139CrossRef

33.

Warraich HJ, Lu D, Cobb S et al (2018) Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. Am Heart J 199:92–96CrossRef

34.

Durand CM, Bowring MG, Thomas AG et al (2018) The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Ann Intern Med 168:702–711CrossRef

35.

Ising MS, Gallo M, Whited WM, Slaughter MS, Trivedi JR (2018) Changing demographics of heart donors: The impact of donor drug intoxication on posttransplant survival. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 18:1790–1798CrossRef

36.

Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G (2018) Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol 15:151–166CrossRef

37.

Kalla A, Krishnamoorthy PM, Gopalakrishnan A, Figueredo VM (2018) Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample. J Cardiovasc Med (Hagerstown) 19:480–484CrossRef

38.

Kariyanna PT, Jayarangaiah A, Singh N et al (2018) Marijuana Induced Myocarditis: A New Entity of Toxic Myocarditis. American journal of medical case reports 6:169–172CrossRef

39.

Nogi M, Fergusson D, Chiaco JM (2014) Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report. Hawai’i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health 73:115–118

40.

Xu DS, Hartman D, Ludrosky K et al (2010) Impact of donor high-risk social behaviors on recipient survival in cardiac transplantation. Transplantation 89:873–878CrossRef

Title: Donor substance abuse and heart transplantation outcomes
Authors: Mohammad Sabra
Onyedika Ilonze
Roopa A. Rao
Kashif Saleem
Maya E. Guglin
Publication date: 18-04-2022
Publisher: Springer US
Keywords: Heart Transplantation
Opioids
Opioids
Heart Failure
Heart Transplantation
Heart Transplantation
Heart Transplantation
Heart Transplantation
Published in: Heart Failure Reviews / Issue 1/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-022-10241-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Donor substance abuse and heart transplantation outcomes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Combined pre- and post-capillary pulmonary hypertension in left heart disease

The value of myocardial strain imaging in the evaluation of patients with repaired Tetralogy of Fallot: a review of the literature

Transition to heart transplantation in post-myocardial infarction ventricular septal rupture: a systematic review

Relationships among norepinephrine levels, exercise capacity, and chronotropic responses in heart failure patients

Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction

PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page